CA-ARRCUS
18.7.2024 15:01:36 CEST | Business Wire | Press release
Arrcus, the hyperscale networking software company and a leader in core, edge, and multi-cloud routing and switching infrastructure, today announced a significant new investment of $30 million from Prosperity7 Ventures, NVIDIA, Lightspeed, Hitachi Ventures, Liberty Global, Clear Ventures, and General Catalyst. Growing investor interest in the company comes alongside Arrcus’ success with leading Fortune 500 and Global 2000 customers and will enable the company to expand platform support, accelerate growth, and continue delivering cost-effective and transformational networking solutions to customers worldwide.
As the unprecedented adoption of AI continues, there is a growing need for distributed networking to improve the efficiency of compute infrastructure spanning datacenter, 5G, edge and hybrid/multi-cloud environments across enterprise, cloud, and network operators. Arrcus’ uniquely differentiated routing and switching platform, Arrcus Connected Edge (ACE), features a distributed microservices architecture that is flexible, high-performance, scalable, fully programmable, modular, and hybrid cloud-ready. It is deployable on various form factors, including data processing units (DPUs), merchant silicon, and compute, and enables a wide range of use cases including low-latency data center networking, modern edge deployments, telco access and transport, and hybrid multi-cloud connectivity.
Arrcus’ ACE networking platform, leveraging the NVIDIA BlueField DPU, enables customers to efficiently offload, accelerate, and isolate compute-intensive networking applications like security and traffic engineering. With the advent of GenAI applications, this gives customers the ability to have high performance secure connectivity within the data center, while delivering higher utilization and power efficiency for compute-intensive workloads.
"We are thrilled to welcome NVIDIA as our latest investor and look forward to building on our collaboration. Arrcus’ leading networking software coupled with NVIDIA's AI infrastructure will help deliver maximum efficiency to customers from data centers as well as their edge and cloud computing environments," said Shekar Ayyar, Chairman and CEO of Arrcus. "We also extend our gratitude to Prosperity7, Lightspeed, Hitachi Ventures, Liberty Global, Clear Ventures, and General Catalyst for their continued support and confidence in our vision."
This collaboration between NVIDIA and Arrcus can help extend AI data center architectures to distributed configurations supported by modular designs such as the NVIDIA MGX platform.
“Modern networks are evolving to address customer needs in the era of AI,” said Kevin Deierling, senior vice president of networking at NVIDIA. “We’re collaborating with Arrcus to provide high-performance, secure and cost-efficient data center networking for a variety of accelerated computing applications.”
Arrcus is garnering significant attention for its innovative networking software solutions that enable businesses to achieve substantial cost savings while improving scalability, performance, and reliability in core, edge, and multi-cloud infrastructures. Arrcus networking is ideally suited for the telecom, financial services, and industrial verticals, amongst others.
“AI is driving the need for more flexible networking to maximize the impact of high-performance compute cycles,” said Jason Hardy, CTO for AI, Hitachi Vantara. “We are pleased to see Arrcus software working across leading industry hardware platforms for distributed datacenter networking.”
“We are excited to see the new investment in Arrcus. Arrcus networking has the potential for high performance at lower cost for datacenter and carrier networks, as well as meeting the demands of infrastructure for AI and 5G,” said Adrian Drury, MD Platform Technology Liberty Global.
“Arrcus is driving an exciting disruption in networking for datacenters and AI. After leading their D round, we are now excited to join NVIDIA and other investors in continuing to support their growth and platform adoption among leading customers,” said Abhishek Shukla, Managing Director, Prosperity7 Ventures.
"Arrcus continues to push the boundaries of networking innovation with their ACE platform. Their unique approach to leveraging distributed microservices architecture and integration with leading hardware platforms enables a wide range of networking use cases from the edge to datacenters to multi-clouds, setting them apart in the industry,” said Alan Weckel, Co-Founder and Technology Analyst at 650 Group. “This new investment further validates Arrcus' vision and capability to deliver high-performance, scalable, and cost-efficient networking solutions that meet the evolving demands of AI-driven environments."
For more information please click here.
Additional Resources
- Arrcus to demonstrate secure 5G networking on NVIDIA BlueField-3 DPUs
- Arrcus Delivers Next Generation of High-Performance, Zero-Trust Networking for Datacenters Enabled by NVIDIA BlueField
- Investor interest in Arrcus grows as Hitachi Ventures is latest to join Series D
About Arrcus
Arrcus is a leading provider of networking software solutions that empower businesses to achieve unparalleled scalability, performance, and reliability in their infrastructure. Arrcus is disrupting the industry with disaggregated solutions that deliver innovative, agile, and cost-effective networking, allowing enterprises to break free from traditional, monolithic systems and embrace a more flexible, efficient, and scalable approach to modern networking. The Arrcus team consists of world-class technologists who have an unparalleled record in shipping industry-leading networking products, complemented by industry thought leaders, operating executives, strategic partners, and top-tier VCs. The company is headquartered in San Jose, Calif. For more information, go to www.arrcus.com or follow Arrcus on LinkedIn and Twitter/X.
About Prosperity7
Prosperity7 Ventures (P7) is the diversified growth fund of Aramco Ventures, a subsidiary of Aramco, the world's leading integrated energy and chemicals company. The fund's name derives from "Prosperity Well', the 7th oil well drilled in Saudi Arabia and the first to strike oil. Taking forward this pioneering history, P7 invests globally with a long-term view in breakthrough technologies and transformational business models that will bring prosperity and positive impact on a vast scale.
For more information, please visit https://www.prosperity7vc.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718299242/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
